Form 4: Voyager Therapeutics CFO Nathan Jorgensen Reports Stock and Option Awards
SEC Form 4 Filing
Chief Financial Officer of Voyager Therapeutics, Nathan D. Jorgensen, reports the acquisition of stock and option awards.
Summary
- On February 21, 2025, Nathan D. Jorgensen, the CFO of Voyager Therapeutics, Inc., was granted 51,500 restricted stock units (RSUs) and an option to purchase 103,000 shares of common stock.
- The RSUs vest over three years, with one-third vesting annually starting February 21, 2026, subject to continued service.
- The stock option, with an exercise price of $4.22, vests over four years, with 1/48th of the shares vesting monthly starting March 21, 2025, subject to continued service.
- Following these transactions, Jorgensen beneficially owns 131,500 shares of common stock and options for 103,000 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Industry Context
Equity compensation is a common practice in the biotechnology industry to attract and retain key executives. The vesting schedules are designed to align management's interests with the long-term performance of the company.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation components for executives in biotech companies like Voyager Therapeutics.
- Companies such as Biogen, Sarepta Therapeutics, and Bluebird Bio also utilize similar equity-based compensation plans to incentivize their leadership teams.
- Vesting schedules of 3-4 years are typical to ensure long-term commitment and alignment with shareholder value creation.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/21/2025 | Date of earliest transaction, grant date of RSUs and stock options |
| 02/21/2026 | First vesting date for 1/3 of the RSU award |
| 02/21/2035 | Expiration date of the stock options |
| 02/24/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.